The adverse effects of irinotecan are primarily due to its active metabolite, SN-38. Common adverse effects include neutropenia, diarrhea, nausea, vomiting, alopecia, and fatigue.

New regimens and administration schedules are under investigation to reduce the adverse effects that cause limitations on irinotecan use.